Navigation Links
Ben-Gurion University Alzheimer's researcher demonstrates specific immune response to vaccine
Date:9/21/2009

BEER-SHEVA, September, 21 2009 A researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients. This continuing research at Ben-Gurion University of the Negev could one day lead to specific Alzheimer's vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.

Amyloid beta-peptide accumulates in the brain of AD patients where it appears to promote neuronal damage. In the new article published in the Journal of Immunology, BGU researcher Dr. Alon Monsonego determined that introducing A-beta into the brain triggers a natural immune response which can be detected in humans.

Importantly, the research team showed that the specificity and magnitude of this body response to A-beta depends on certain key genes of the immune system, which are highly polymorphic in the population (this means that except for identical twins, almost each of us has a different combination of genes termed "HLA alleles").

Furthermore, this research took an unusual approach combining humans and humanized mouse models. "We began with characterizing the genes in humans in a collaboration with the laboratories of Dr. Weiner and Dr. Selkoe at Harvard, then did the same study in mice using a mouse model of multiple sclerosis witht the laboratory of Dr. Altmann- Imperial College School of Medicine, UK," Monsonego explains. "We then generated a humanized mouse model of AD, with a specific gene that was present in approximately 30 percent of our study group (HLA DR15 allele). Conceivably, those people that have this gene could receive the same vaccine which will teach a person's immune system to better fight the disease."

Monsonego continues, "As in other mouse models of the disease, we show that with aging A-beta aggregates accumulate in brain areas of cognitive functions and stimulate an inflammatory reaction in the brain. However, stimulating an immune response to A-beta in these humanized mice not only resulted in a highly efficient clearance of A-beta (plaque) from the brain, but also in a markedly reduced inflammatory reaction. Furthermore, we were able to predict that the characteristics of immune response in mice were the same as in the humans.

"This study thus provides the basis for developing an individual-based (personalized medicine) immunotherapeutic approach to Alzheimer's disease since different populations will respond differently to a vaccine based on their genetic background," Monsonego explains. "Now that we've proven we can anticipate the specific responses for several abundant genes in the population, further study is needed to ensure safety and efficacy in our humanized mouse model of AD."

Dr. Monsonego, who holds the Zehava and Chezy Vered Career Development Chair for the Study of Alzheimer's and Neurodegenerative Diseases, is a member of BGU's Shraga Segal Department of Microbiology and Immunology and the National Institute for Biotechnology in the Negev.

The research is funded in part by the Israel Science Foundation, the Alzheimer Association and by the New York real estate developer Leonard Litwin and the Aaron Gural family.

"It is so rewarding to see how donors of American Associates, Ben-Gurion University of the Negev are contributing to the groundbreaking progress on discovering a viable Alzheimer's vaccine," states Executive Vice President Doron Krakow. "It's another example of how BGU's research helps people around the world."


'/>"/>

Contact: Andrew Lavin
alc@alavin.com
516-353-2505
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Related biology news :

1. Ben-Gurion University of the Negev technology being developed for use in Jordan desalination plant
2. Ben-Gurion U. developing new computer techniques to analyze historic Hebrew and Arabic documents
3. 1 in 6 health workers wont report in flu pandemic -- study by Ben-Gurion U. researchers
4. Ben-Gurion U. researchers reveal connection between cancer and human evolution
5. Ben-Gurion University research and technology used in new solar energy farm
6. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
7. Ben-Gurion University engineers develop technique to help combat nuclear proliferation
8. Ben-Gurion University of the Negev researchers develop new reversible, green window technology
9. Ben-Gurion University of the Negev to host
10. Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia
11. Environmental peace treaty between Israel and Palestinians unveiled at Ben-Gurion University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... ... May 23, 2016 , ... ... Drive Precision Farming in 2017 and Beyond. The paper outlines the key trends ... precision ag industry. , “We’ve witnessed a lot of highs and lows as ...
(Date:5/23/2016)... and LONDON , May 23, 2016 /PRNewswire/ ... See Frontage Boost Efficiency by 40% - Frontage Implement ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... labs in the United States and ... to be deployed across its laboratory facilities. In addition to serving ...
(Date:5/22/2016)... ... 22, 2016 , ... Doctors in Rome say micronutrients found in certain foods ... Surviving Mesothelioma has just posted an article on the new research. Click here ... Clinical Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in cancer ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or ... way to treat the disease. Surviving Mesothelioma has just posted an article on the ... Korean institutions based their mesothelioma study on the fact the Manumycin A, a derivative ...
Breaking Biology Technology: